Salarius Pharmaceuticals, Inc. (SLRX)
USD 1.22
(-8.27%)
USD 1.22
(-8.27%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.84 Million | -17.59 Million | -10.2 Million | -10.31 Million | -11.58 Million | -23.59 Million |
| Net Income | -12.54 Million | -31.6 Million | -12.76 Million | -7.35 Million | -6.93 Million | -21.92 Million |
| Depreciation & Amortization | 10.05 Thousand | 6677.00 | 19.18 Thousand | 18.05 Thousand | 127.4 Thousand | 228.15 Thousand |
| Deferred income taxes | -1.31 Million | - | - | - | - | 11.53 Thousand |
| Stock-based compensation | 524.83 Thousand | 796.8 Thousand | 559.04 Thousand | 319.39 Thousand | 751.61 Thousand | 1.93 Million |
| Change in working capital | -968.33 Thousand | 2.36 Million | 2.03 Million | -3.03 Million | -4.21 Million | -3.87 Million |
| Other non-cash items | 1.44 Million | 10.83 Million | -44.69 Thousand | -258.55 Thousand | -1.31 Million | 20.31 Thousand |
| Investing Cash Flow | - | -1.5 Million | - | -2600.00 | 5.6 Million | 14.12 Million |
| Investments in PPE | -3.00 | -1.5 Million | - | -2600.00 | - | - |
| Acquisitions | - | - | - | - | 5.6 Million | - |
| Investment purchases | - | - | - | - | - | -1.99 Million |
| Sales/Maturities of investments | - | - | - | - | - | 16.11 Million |
| Other Investing Activities | - | -1.5 Million | - | - | 204.27 Thousand | 4805.00 |
| Financing Cash Flow | 6.63 Million | 1.98 Million | 28.29 Million | 17.69 Million | 3.57 Million | 118.01 Thousand |
| Debt repayment | -280.91 Thousand | - | -477.02 Thousand | -974.43 Thousand | -417.88 Thousand | - |
| Dividends payments | - | - | - | - | -133.59 Thousand | - |
| Common Stock Repurchased | - | - | - | - | -3.71 Million | -615.01 Thousand |
| Common Stock Issuance | 6.92 Million | 1.98 Million | 27.28 Million | 14.79 Million | 4.13 Million | 118.01 Thousand |
| Other Financing Activities | 6639.61 | 1987.38 | 1.48 Million | 3.86 Million | 3.71 Million | 1435.25 |
| Accounts receivables | 1.48 Million | - | 2.24 Million | -3.85 Million | 690.00 | 7206.00 |
| Accounts payables | -2.25 Million | 1.31 Million | -310.66 Thousand | -2782.00 | -519.27 Thousand | -1.66 Million |
| Inventory | -1.00 | - | -2.24 Million | 3.85 Million | 1169.00 | 227.97 Thousand |
| Other working capital | -193.34 Thousand | 1.05 Million | 2.34 Million | -3.03 Million | -3.69 Million | -2.44 Million |
| Cash at beginning of period | 12.1 Million | 29.21 Million | 11.11 Million | 3.73 Million | 6.13 Million | 19.31 Million |
| Cash at end of period | 5.89 Million | 12.1 Million | 29.21 Million | 11.11 Million | 3.73 Million | 9.95 Million |
| Capital Expenditure | -3.00 | -1.5 Million | - | -2600.00 | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -6.2 Million | -17.1 Million | 18.09 Million | 7.37 Million | -2.39 Million | -9.35 Million |
| Free Cash Flow | -12.84 Million | -19.09 Million | -10.2 Million | -10.31 Million | -11.58 Million | -23.59 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.42 Million | -1.71 Million | -881.79 Thousand | -12.54 Million | -2.44 Million | -3.87 Million |
| Depreciation & Amortization | 1106.00 | 1107.00 | 1105.00 | 10.05 Thousand | 5608.00 | 1669.00 |
| Deferred income taxes | - | - | -573.37 Thousand | -1.31 Million | - | 94.08 Thousand |
| Stock-based compensation | 85.16 Thousand | 77.5 Thousand | 85.37 Thousand | 524.83 Thousand | 112.65 Thousand | 123.45 Thousand |
| Change in working capital | 265.96 Thousand | 282.72 Thousand | -715.91 Thousand | -968.33 Thousand | -1.55 Million | -664.26 Thousand |
| Other non-cash items | 181.87 Thousand | -31.38 Thousand | 573.37 Thousand | 1.44 Million | 130 Thousand | -94.08 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | 2.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -28.19 Thousand | -172.75 Thousand | -169.44 Thousand | 6.63 Million | -211.82 Thousand | 6.68 Million |
| Debt repayment | -116.85 Thousand | -172.78 Thousand | -169.44 Thousand | -280.91 Thousand | -111.46 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -100.36 | - |
| Common Stock Issuance | 88.66 Thousand | 38.00 | -1.00 | 6.92 Million | -100.36 Thousand | 6.68 Million |
| Other Financing Activities | -28.19 | -172.75 | -169.45 | 6639.61 | 111.66 Thousand | 6684.21 |
| Accounts receivables | - | - | -1.48 Million | 1.48 Million | - | - |
| Accounts payables | -94.49 Thousand | 111.1 Thousand | -485.78 Thousand | -2.25 Million | -1.09 Million | -1.29 Million |
| Inventory | - | - | 1.48 Million | -1.00 | - | - |
| Other working capital | 360.45 Thousand | 171.61 Thousand | -230.12 Thousand | -193.34 Thousand | -456.29 Thousand | 634.81 Thousand |
| Cash at beginning of period | 4.37 Million | 5.89 Million | 7.58 Million | 12.1 Million | 11.54 Million | 9.27 Million |
| Cash at end of period | 3.27 Million | 4.37 Million | 5.89 Million | 5.89 Million | 7.58 Million | 11.54 Million |
| Capital Expenditure | 2.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.1 Million | -1.52 Million | -1.68 Million | -6.2 Million | -3.96 Million | 2.26 Million |
| Free Cash Flow | -1.07 Million | -1.35 Million | -1.51 Million | -12.84 Million | -3.74 Million | -4.41 Million |
5484
EQLB
TQLB
ARD
8033
CLOQ